I know some think that failure on top-line might be salvagable if secondary outcomes for things like eGFR and MOCA scores are positive...I don't agree.

GAC - in the short term you’re probably right.  But, provided the long-term financial benefits of commercialization outweigh the costs then continued R&D for those secondary outcomes is likely.  So, perhaps still salvageable but certainly not anytime soon.